Merck receives complete response letter from FDA for sBLAs for KEYTRUDA six-week dosing schedule
The submitted applications are based on pharmacokinetic modeling and simulation data presented at the 2018 ASCO Annual Meeting. These data supported the European Commission approval of 400 mg